About this trial
At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficiency of providing medical care to patients with acute coronary syndrome (ACS), there remains a high mortality and disability of this group of patients. In this regard, the search for new drug and non-drug strategies for the treatment of patients with ACS is actively continuing. Over the past decade, it has been shown that transcutaneous vagus nerve stimulation (TENS) has a cardioprotective effect both in chronic heart failure and in coronary heart disease, improves cardiac function, prevents reperfusion injury, weakens myocardial remodeling, increases the effectiveness of defibrillation and reduces the size of a heart attack. One of the methods of noninvasive stimulation of the afferent fibers of the vagus nerve is percutaneous electrical stimulation of the auricular branch of the vagus nerve. However, further studies are needed to determine whether stimulation of the tragus can improve the long-term clinical outcome in this cohort of patients.
Eligibility criteria
Qualifiers
patients with STEMI who have signed an informed voluntary consent to participate in the study;
primary myocardial infarction;
treatment in the first 12 hours from the onset of pain syndrome;
primary PCI.
Disqualifiers
acute heart failure III-IV;
bradyarrhythmias;
atrial fibrillation/flutter at the time of switching on;
Thrombolytic therapy at the prehospital stage;
Trial design
Treatments tested in this trial
- TENS
Treatment groups
Sponsors and collaborators
Bakulev Scientific Center of Cardiovascular Surgery
Lead sponsor
State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
Collaborator